This review discusses peptide epitopes used as antigens in the development of vaccines in clinical trials as well as future vaccine candidates. It covers peptides used in potential immunotherapies for infectious diseases including SARS-CoV-2, influenza, hepatitis B and C, HIV, malaria, and others. In addition, peptides for cancer vaccines that target examples of overexpressed proteins are summarized, including human epidermal growth factor receptor 2 (HER-2), mucin 1 (MUC1), folate receptor, and others. The uses of peptides to target cancers caused by infective agents, for example, cervical cancer caused by human papilloma virus (HPV), are also discussed. This review also provides an overview of model peptide epitopes used to stimulate non-specific immune responses, and of self-adjuvanting peptides, as well as the influence of other adjuvants on peptide formulations. As highlighted in this review, several peptide immunotherapies are in advanced clinical trials as vaccines, and there is great potential for future therapies due the specificity of the response that can be achieved using peptide epitopes.
Keyphrases
- clinical trial
- epidermal growth factor receptor
- sars cov
- endothelial cells
- immune response
- infectious diseases
- amino acid
- hiv infected
- induced pluripotent stem cells
- randomized controlled trial
- antiretroviral therapy
- squamous cell carcinoma
- human immunodeficiency virus
- climate change
- toll like receptor
- phase ii
- pluripotent stem cells
- high grade
- coronavirus disease
- binding protein
- double blind